Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid.
Friedman ES, Li Y, Shen TD, Jiang J, Chau L, Adorini L, Babakhani F, Edwards J, Shapiro D, Zhao C, Carr RM, Bittinger K, Li H, Wu GD. Friedman ES, et al. Among authors: adorini l. Gastroenterology. 2018 Dec;155(6):1741-1752.e5. doi: 10.1053/j.gastro.2018.08.022. Epub 2018 Aug 23. Gastroenterology. 2018. PMID: 30144429 Free PMC article. Clinical Trial.
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D. Mudaliar S, et al. Among authors: adorini l. Gastroenterology. 2013 Sep;145(3):574-82.e1. doi: 10.1053/j.gastro.2013.05.042. Epub 2013 May 30. Gastroenterology. 2013. PMID: 23727264 Clinical Trial.
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, Vincent C, Bodhenheimer HC Jr, Parés A, Trauner M, Marschall HU, Adorini L, Sciacca C, Beecher-Jones T, Castelloe E, Böhm O, Shapiro D. Hirschfield GM, et al. Among authors: adorini l. Gastroenterology. 2015 Apr;148(4):751-61.e8. doi: 10.1053/j.gastro.2014.12.005. Epub 2014 Dec 11. Gastroenterology. 2015. PMID: 25500425 Free article. Clinical Trial.
Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension.
Vignozzi L, Morelli A, Cellai I, Filippi S, Comeglio P, Sarchielli E, Maneschi E, Vannelli GB, Adorini L, Maggi M. Vignozzi L, et al. Among authors: adorini l. J Steroid Biochem Mol Biol. 2017 Jan;165(Pt B):277-292. doi: 10.1016/j.jsbmb.2016.07.004. Epub 2016 Jul 15. J Steroid Biochem Mol Biol. 2017. PMID: 27425465
Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis.
Comeglio P, Filippi S, Sarchielli E, Morelli A, Cellai I, Corcetto F, Corno C, Maneschi E, Pini A, Adorini L, Vannelli GB, Maggi M, Vignozzi L. Comeglio P, et al. Among authors: adorini l. J Steroid Biochem Mol Biol. 2017 Apr;168:26-37. doi: 10.1016/j.jsbmb.2017.01.010. Epub 2017 Jan 20. J Steroid Biochem Mol Biol. 2017. PMID: 28115235
Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
Erice O, Labiano I, Arbelaiz A, Santos-Laso A, Munoz-Garrido P, Jimenez-Agüero R, Olaizola P, Caro-Maldonado A, Martín-Martín N, Carracedo A, Lozano E, Marin JJ, O'Rourke CJ, Andersen JB, Llop J, Gómez-Vallejo V, Padro D, Martin A, Marzioni M, Adorini L, Trauner M, Bujanda L, Perugorria MJ, Banales JM. Erice O, et al. Among authors: adorini l. Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1335-1344. doi: 10.1016/j.bbadis.2017.08.016. Epub 2017 Sep 13. Biochim Biophys Acta Mol Basis Dis. 2018. PMID: 28916388 Free article.
332 results